Please assess the completion status of the following clinical trial:

Trial Title: IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically stable participants may be eligible to enroll within 10 days following hospital admission with high-risk acute coronary syndrome (either ST-elevation myocardial infarction \[STEMI\] or Non-STEMI or unstable angina)~* Participants not taking a statin must have an LDL-C of 125 mg/dl or less. Participants taking a statin must have an LDL-C of 100 mg/dl or less.~Exclusion Criteria:~* Pregnant or lactating woman, or intending to become pregnant~* Participant with active liver disease or persistent unexplained serum transaminase elevation~* History of alcohol or drug abuse~* History of sensitivity to statin or ezetimibe~* A participant for whom discontinuation of existing lipid lowering regimen poses an unacceptable risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ezetimibe/simvastatin (Type: EXPERIMENTAL): One Ezetimibe 10 mg/simvastatin 40 mg combination tablet and two simvastatin 40 mg placebo tablets once per day.
- simvastatin (Type: ACTIVE_COMPARATOR): One simvastatin 40 mg tablet, one ezetimibe/simvastatin combination 10/40 placebo tablet and one simvastatin 40 mg placebo tablet once per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).